Alimera Sciences Inc   (ALIM)
Other Ticker:  
Price: $3.5000 $0.12 3.550%
Day's High: $3.55 Week Perf: 7.69 %
Day's Low: $ 3.34 30 Day Perf: -10.71 %
Volume (M): 70 52 Wk High: $ 4.38
Volume (M$): $ 246 52 Wk Avg: $3.01
Open: $3.50 52 Wk Low: $1.30

 Market Capitalization (Millions $) 112
 Shares Outstanding (Millions) 32
 Employees -
 Revenues (TTM) (Millions $) 67
 Net Income (TTM) (Millions $) -20
 Cash Flow (TTM) (Millions $) 3
 Capital Exp. (TTM) (Millions $) 76

Alimera Sciences Inc
Alimera Sciences Inc is a pharmaceutical company that specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company primarily focuses on diseases affecting the retina, such as diabetic macular edema and age-related macular degeneration. Alimera Sciences has developed an implantable drug delivery system called ILUVIEN, which is used to treat these retinal diseases. The company is dedicated to improving the lives of patients with vision impairments and providing innovative solutions in the field of ophthalmology. Alimera Sciences Inc is headquartered in Alpharetta, Georgia, and operates globally in various markets.

   Company Address: 6310 Town Square Alpharetta 30005 GA
   Company Phone Number: 990-5740   Stock Exchange / Ticker: NASDAQ ALIM
   ALIM is expected to report next financial results on March 30, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Alimera's Breakthrough Synchronicity Study with YUTIQ Surges Past Recruitment Goal: A Game-Changer in Ophthalmology

Published Thu, Jan 4 2024 1:01 PM UTC

Alimera Sciences, a renowned pharmaceutical company specializing in ophthalmic solutions, recently announced the completion of patient recruitment for their groundbreaking Synchronicity Study. This significant milestone marks a major breakthrough in the field of ophthalmology, as the study has successfully surpassed its initial goal of enrolling 100 patients.The Synchronicit...

Management Changes

Alimera Sciences Appoints Todd Wood as President U.S. Amidst Financial Turmoil, Gearing Up for Strides in Retinal Health

Published Tue, Dec 12 2023 12:30 PM UTC

Alimera Sciences, a prominent global pharmaceutical company focused on retinal health, recently announced the appointment of Todd Wood as the President of U.S. operations. This strategic move comes as the company strives to deliver its mission of being invaluable to patients, physicians, and partners in maintaining better vision over the long term.
Wood's exten...

Alimera Sciences Inc

Alimera Sciences Inc Achieves Impressive Revenue Surge, Addressing Fiscal Shortfall in 2023

Alimera Sciences Inc Sees Decent Revenue Growth in Third Quarter, Signals Positive Future Performance
November 13, 2023
Alimera Sciences Inc, a leading player in the Major Pharmaceutical Preparations industry, reported a significant increase in revenue for its most recent fiscal period, signaling positive prospects for the company's future. The company's revenue grew by an impressive 66.245% to reach $22.61 million, contributing to a significant reduction in losses from $-0.75 per share in the comparable reporting season a year ago to $-0.06 per share.
Compared to its major competitors in the Major Pharmaceutical Preparations sector, Alimera Sciences Inc's revenue growth outpaced the industry average. In the third quarter of 2023, the company's revenue growth was at 1.30%, while its two closest rivals reported an average growth of only 1.30% relative to the comparable period a year ago.

Alimera Sciences Inc

Alimera Sciences Inc Delivers Stunning Double-Digit Revenue Growth in Latest Fiscal Results, Smashing Expectations

/>Alimera Sciences Inc., a company operating in the Major Pharmaceutical Preparations sector, recently released its financial results for the April to June 30, 2023 time frame. While the company experienced significant growth in revenue, it recorded an increased deficit per share compared to the previous year. This article will outline the key facts from the financial report and provide insight into the current performance and prospects of Alimera Sciences Inc.
Key Points:
1. Deficit per Share:
- Alimera Sciences Inc.'s deficit per share increased to $-1.32 in Q2 2023 from $-0.45 in the previous year.
- This growth in deficit per share reflects a widening loss for the company, indicating financial challenges in the period.
- The deficit per share also grew from $-0.71 in the previous reporting period.

Alimera Sciences Inc

In an impressive surge, Alimera Sciences Inc witnesses a remarkable 13.851% revenue growth during the first quarter of the 2023 earnings season

Alimera Sciences Inc, a pharmaceutical company specializing in treating eye diseases, has reported mixed financial results for the first quarter of the 2023 earnings season. While the company's revenue increased significantly by 13.851% to $13.55 million from the corresponding financial reporting period a year ago, it recorded a net shortfall of $-4.968 million, resulting in a deficit of $-0.71 per share.
Comparing the recent numbers with the prior financial reporting period, the company's revenue decreased by -3.443% from $14.03 million, while the net shortfall increased from $-0.53 per share. It is worth noting that the current net shortfall is lower than the corresponding figure of $-5.955 million a year ago.


Alimera Sciences Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com